DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Dovonex (Calcipotriene Topical) - Summary

 
 



DOVONEX SUMMARY

Dovonex®
(calcipotriene ointment),
0.005%

Dovonex® (calcipotriene ointment), 0.005% contains the compound calcipotriene, a synthetic vitamin D3 derivative for topical dermatological use.

Dovonex (calcipotriene ointment), 0.005%, is indicated for the treatment of plaque psoriasis in adults. The safety and effectiveness of topical calcipotriene in dermatoses other than psoriasis have not been established.
See all Dovonex indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Dovonex (Calcipotriene Topical)

Weight Loss Might Ease Psoriasis, Study Hints
Source: MedicineNet Obesity (Weight Loss) Specialty [2013.05.30]
Title: Weight Loss Might Ease Psoriasis, Study Hints
Category: Health News
Created: 5/29/2013 4:35:00 PM
Last Editorial Review: 5/30/2013 12:00:00 AM

Diet May Ease Psoriasis Symptoms (CME/CE)
Source: MedPage Today Dermatology [2013.05.29]
(MedPage Today) -- Putting psoriasis patients on a low-calorie diet may improve quality of life and reduce psoriasis severity, researchers found.

Psoriasis
Source: MedicineNet Actinic Keratosis Specialty [2013.05.16]
Title: Psoriasis
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 5/16/2013 12:00:00 AM

Scalp Psoriasis
Source: MedicineNet Hair Loss Specialty [2013.05.16]
Title: Scalp Psoriasis
Category: Diseases and Conditions
Created: 7/24/2012 3:21:00 PM
Last Editorial Review: 5/16/2013 12:00:00 AM

Kids With Psoriasis More Likely to Be Overweight: Study
Source: MedicineNet Psoriasis Specialty [2012.11.20]
Title: Kids With Psoriasis More Likely to Be Overweight: Study
Category: Health News
Created: 11/19/2012 4:36:00 PM
Last Editorial Review: 11/20/2012 12:00:00 AM

more news >>

Published Studies Related to Dovonex (Calcipotriene Topical)

Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis: results of two multicenter, randomized, double-blind, vehicle-controlled, phase III clinical trials. [2012]
plaque-type psoriasis... CONCLUSIONS: In two identically designed, phase III clinical trials,

A calcipotriene/betamethasone dipropionate two-compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients: results of the randomized, 8-week, double-blind phase of a clinical trial. [2010.11]
The calcipotriene/betamethasone dipropionate two-compound scalp formulation has been shown to be safe and effective in the treatment of scalp psoriasis over 8 weeks, but the patients studied were mainly White and non-Hispanic. The aim of this study was to evaluate the efficacy and safety of the two-compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients...

Pilot, multicenter, double-blind, randomized placebo-controlled bilateral comparative study of a combination of calcipotriene and nicotinamide for the treatment of psoriasis. [2010.11]
BACKGROUND: Calcipotriene has limited efficacy in treating psoriasis. By inhibiting proinflammatory cytokines such as interleukin-12, interleukin-23, and tumor necrosis factor-alfa, nicotinamide may enhance the efficacy of calcipotriene therapy when used in combination. OBJECTIVE: We sought to determine if the combination of nicotinamide with calcipotriene is more effective than either component alone... CONCLUSION: This study provides evidence that using the combination nicotinamide and calcipotriene may provide additional benefit in the topical treatment for patients with psoriasis and may be an adequate steroid-sparing substitute treatment. Copyright (c) 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Short- and long-term safety assessment of a two-compound ointment containing calcipotriene/betamethasone dipropionate (Taclonex/Daivobet/Dovobet ointment): hypothalamic-pituitary-adrenal axis function in patients with psoriasis vulgaris. [2010.08]
The two-compound ointment (Taclonex/Daivobet/Dovobet ointment) combining calcipotriene 50 microg/g and betamethasone 0.5 mg/g (as dipropionate) is very effective in the treatment of psoriasis vulgaris... No patients using the two-compound ointment for all 52 weeks or alternating four-weekly with calcipotriene had HPA axis suppression.

Pilot, multicenter, double-blind, randomized placebo-controlled bilateral comparative study of a combination of calcipotriene and nicotinamide for the treatment of psoriasis. [2010.07.02]
BACKGROUND: Calcipotriene has limited efficacy in treating psoriasis. By inhibiting proinflammatory cytokines such as interleukin-12, interleukin-23, and tumor necrosis factor-alfa, nicotinamide may enhance the efficacy of calcipotriene therapy when used in combination. OBJECTIVE: We sought to determine if the combination of nicotinamide with calcipotriene is more effective than either component alone... CONCLUSION: This study provides evidence that using the combination nicotinamide and calcipotriene may provide additional benefit in the topical treatment for patients with psoriasis and may be an adequate steroid-sparing substitute treatment. Copyright (c) 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

more studies >>

Clinical Trials Related to Dovonex (Calcipotriene Topical)

Efficacy and Safety of Calcipotriol Cream and (Calcipotriol + Betamethasone Dipropionate) Ointment in Psoriasis Vulgaris [Completed]
Patients with psoriasis vulgaris of the trunk and/or limbs are randomised to treatment with:

1. 4 weeks of ointment containing calcipotriol and betamethasone dipropionate followed by 8 weeks of calcipotriol cream

2. 4 weeks of (calcipotriol plus betamethasone dipropionate) ointment followed by 8 weeks of calcipotriol cream on weekdays/ (calcipotriol plus betamethasone dipropionate) ointment on weekends

3. 4 weeks of (calcipotriol plus betamethasone dipropionate) ointment followed by 8 weeks of vehicle of calcipotriol cream

The objective is to compare the efficacy and safety of the different treatment regimens

An Exploratory Psoriasis Plaque Test Study With LEO 29102 Plus Calcipotriol, Ointment, in Psoriasis Vulgaris [Recruiting]

Efficacy of Calcipotriol Plus Betamethasone Gel Versus Calcipotriol Scalp Solution in Scalp Psoriasis [Completed]
The purpose of this study is to evaluate whether once daily treatment for up to 8 weeks of calcipotriol plus betamethasone dipropionate gel is more effective than twice daily treatment of calcipotriol scalp solution in patients with scalp psoriasis. The primary outcome is patients with clear or minimal disease after 8 weeks treatment.

Further the occurrence of relapse and rebound after end of treatment in patients with clear or minimal disease will be investigated.

Efficacy and Safety of Calcipotriene/Betamethasone Gel/Ointment in Psoriasis [Completed]
Patients will receive either a gel containing both calcipotriene plus betamethasone or gel with no active ingredients as treatment for their scalp psoriasis for 8 weeks. After this time all patients will receive the gel containing both calcipotriene and betamethasone for 44 weeks. In addition, patients will receive an ointment containing both calcipotriene plus betamethasone as treatment for their psoriasis of the trunk and limbs for 52 weeks.

The objective is to study the short-term efficacy of the gel, and the short and long-term safety of the gel and the ointment.

The Role of Calcipotriol as Radioprotector of Skin [Not yet recruiting]
Examining the hypothesis that protecting keratinocytes by calcipotriol can prevent in-vivo cutaneous side effect in patients receiving radiotherapy to the breast.

To check the connection between the skin effect of radiotherapy and different parameters including diseases such as diabetes and lupus, use of medications, allergies, weight, habits, size of the irradiated breast, previous chemotherapy treatment and exposure to sunlight.

more trials >>


PATIENT REVIEWS / RATINGS / COMMENTS

Based on a total of 1 ratings/reviews, Dovonex has an overall score of 6. The effectiveness score is 6 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.
 

Dovonex review by 29 year old female patient

  Rating
Overall rating:  
Effectiveness:   Moderately Effective
Side effects:   No Side Effects
  
Treatment Info
Condition / reason:   Psoriasis
Dosage & duration:   .005% (dosage frequency: 1-2 times daily) for the period of 4 years
Other conditions:   None
Other drugs taken:   Clobetasol
  
Reported Results
Benefits:   Controlled the psoriasis, however did not reduce its presence.
Side effects:   a "halo" a few shades lighter than the natural skin tone was present around the site of application, which would last about 12-24 hours.
Comments:   I found this time-consuming to apply 1-2 times daily. Also, due to the "halo" effect, it was a little precarious to apply as well.

See all Dovonex reviews / ratings >>

Page last updated: 2013-05-30

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012